NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme Inc (NASDAQ:EPZM) issued its quarterly earnings results on Monday, February, 24th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.08. The biopharmaceutical company had revenue of $4.29 million for the quarter, compared to analysts' expectations of $2.83 million. Epizyme had a negative return on equity of 58.35% and a negative net margin of 715.53%. View Epizyme's Earnings History.

Epizyme is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Epizyme.

7 brokerages have issued 1 year price targets for Epizyme's shares. Their forecasts range from $18.00 to $36.00. On average, they expect Epizyme's stock price to reach $30.50 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price. View Analyst Price Targets for Epizyme.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

News coverage about EPZM stock has trended positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Epizyme earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Epizyme.

Epizyme saw a increase in short interest in January. As of January 15th, there was short interest totalling 8,780,000 shares, an increase of 9.5% from the December 31st total of 8,020,000 shares. Based on an average daily trading volume, of 919,900 shares, the short-interest ratio is presently 9.5 days. Currently, 11.5% of the company's shares are short sold. View Epizyme's Current Options Chain.

Some companies that are related to Epizyme include Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Horizon Therapeutics (HZNP), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA), Amarin (AMRN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Evotec (EVTCY), GW Pharmaceuticals PLC- (GWPH) and FibroGen (FGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Amarin (AMRN), Clovis Oncology (CLVS), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Novavax (NVAX), TG Therapeutics (TGTX) and Verastem (VSTM).

Epizyme's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (6.75%), Victory Capital Management Inc. (2.91%), Victory Capital Management Inc. (2.73%), State Street Corp (2.71%), FMR LLC (2.45%) and Loomis Sayles & Co. L P (1.76%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Institutional Ownership Trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, FMR LLC, State Street Corp, Palo Alto Investors LP, UBS Group AG, Rafferty Asset Management LLC, Goldman Sachs Group Inc. and Citigroup Inc.. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Insider Buying and Selling for Epizyme.

EPZM stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Victory Capital Management Inc., State of New Jersey Common Pension Fund D, Candriam Luxembourg S.C.A., Delta Investment Management LLC, EAM Investors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Epizyme.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EPZM stock can currently be purchased for approximately $20.47.

Epizyme has a market capitalization of $1.86 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

The official website for Epizyme is http://www.epizyme.com/.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]